
Zevra Therapeutics, Inc. – NASDAQ:ZVRA
Zevra Therapeutics stock price today
Zevra Therapeutics stock price monthly change
Zevra Therapeutics stock price quarterly change
Zevra Therapeutics stock price yearly change
Zevra Therapeutics key metrics
Market Cap | 449.42M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.35 |
Revenue | 28.00M |
EBITDA | -51.52M |
Income | -50.90M |
Revenue Q/Q | 18.96% |
Revenue Y/Y | 198.83% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -183.98% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZevra Therapeutics stock price history
Zevra Therapeutics stock forecast
Zevra Therapeutics financial statements
Jun 2023 | 8.47M | -5.08M | -60.02% |
---|---|---|---|
Sep 2023 | 2.89M | -14.04M | -485.15% |
Dec 2023 | 13.21M | -15.15M | -114.65% |
Mar 2024 | 3.42M | -16.62M | -485.31% |
Sep 2025 | 21.14M | -6.44M | -30.47% |
---|---|---|---|
Oct 2025 | 21.29M | -5.43M | -25.51% |
Dec 2025 | 22.04M | -2.17M | -9.88% |
Dec 2025 | 24.73M | -2.92M | -11.82% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 105518000 | 37.01M | 35.08% |
---|---|---|---|
Sep 2023 | 138982000 | 71.51M | 51.45% |
Dec 2023 | 172327000 | 110.46M | 64.1% |
Mar 2024 | 151283000 | 102.46M | 67.73% |
Jun 2023 | -8.70M | 34.03M | 951K |
---|---|---|---|
Sep 2023 | -4.62M | -44.45M | 26.25M |
Dec 2023 | -16.15M | 10.58M | 5.00M |
Mar 2024 | -16.16M | 14.79M | 1.21M |
Zevra Therapeutics alternative data
Aug 2023 | 32 |
---|---|
Sep 2023 | 32 |
Oct 2023 | 32 |
Nov 2023 | 32 |
Dec 2023 | 32 |
Jan 2024 | 32 |
Feb 2024 | 32 |
Mar 2024 | 32 |
Apr 2024 | 32 |
May 2024 | 65 |
Jun 2024 | 65 |
Jul 2024 | 65 |
Zevra Therapeutics other data
Quarter | Transcript |
---|---|
Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 17 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Zevra Therapeutics stock today?
One share of Zevra Therapeutics stock can currently be purchased for approximately $9.18.
-
When is Zevra Therapeutics's next earnings date?
Unfortunately, Zevra Therapeutics's (ZVRA) next earnings date is currently unknown.
-
Does Zevra Therapeutics pay dividends?
No, Zevra Therapeutics does not pay dividends.
-
How much money does Zevra Therapeutics make?
Zevra Therapeutics has a market capitalization of 449.42M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 162.58% to 27.46M US dollars.
-
What is Zevra Therapeutics's stock symbol?
Zevra Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ZVRA".
-
What is Zevra Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Zevra Therapeutics?
Shares of Zevra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Zevra Therapeutics have?
As Jul 2024, Zevra Therapeutics employs 65 workers, which is 103% more then previous quarter.
-
When Zevra Therapeutics went public?
Zevra Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 16 Apr 2015.
-
What is Zevra Therapeutics's official website?
The official website for Zevra Therapeutics is zevra.com.
-
Where are Zevra Therapeutics's headquarters?
Zevra Therapeutics is headquartered at 1180 Celebration Boulevard, Celebration, FL.
-
How can i contact Zevra Therapeutics?
Zevra Therapeutics's mailing address is 1180 Celebration Boulevard, Celebration, FL and company can be reached via phone at +32 19 39 34 16.
Zevra Therapeutics company profile:

Zevra Therapeutics, Inc.
zevra.comNASDAQ
65
Biotechnology
Healthcare
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Celebration, FL 34747
CIK: 0001434647
ISIN: US4884452065
: